跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 725 条关于
“FXS”
全部
725
临床试验
521
药物
161
机构
3
资讯
40
去年
Fragile X Syndrome Market Set for $83.2M Growth with Novel Therapeutic Approaches
去年
Spinogenix's SPG601 Shows Promise in Phase 2 Trial for Fragile X Syndrome
去年
CONNECTA Therapeutics Advances First-in-Class Neuroplasticity Modulator CTH120 to Phase II for Pediatric Fragile X Syndrome
2年前
FDA Grants Orphan Drug Status to Spinogenix's SPG601 for Fragile X Syndrome
2年前
Spinogenix Receives FDA Orphan Drug Designation for SPG601 to Treat Fragile X Syndrome
2年前
Two Major Breakthroughs in Fragile X Syndrome Treatments
去年
Servier Acquires KER-0193 for $450M to Target Fragile X Syndrome, Marking First Neurology Asset
去年
QurAlis Secures Exclusive License for Novel RNA-Targeted Therapy in Fragile X Syndrome
12个月前
Harmony Biosciences' ZYN002 Phase 3 Trial Fails to Meet Primary Endpoint in Fragile X Syndrome
9个月前
Mirum Pharmaceuticals Initiates Phase II Trial of MRM-3379 for Fragile X Syndrome
第 1 页,共 4 页
上一页
下一页